➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKinsey
Harvard Business School
Colorcon
Express Scripts

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,220,698

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,220,698 protect, and when does it expire?

Patent 9,220,698 protects VIMOVO and is included in one NDA.

This patent has thirty-seven patent family members in twenty-two countries.

Summary for Patent: 9,220,698
Title:Method for delivering a pharmaceutical composition to patient in need thereof
Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.
Inventor(s): Ault; Brian (Wilmington, DE), Sostek; Mark (Wilmington, DE), Orlemans; Everardus (Chapel Hill, NC), Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen Inc. (Chapel Hill, NC) Horizon Pharma USA, Inc. (Deerfield, IL)
Application Number:12/553,107
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,220,698
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,220,698

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes   Start Trial   Start Trial RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,220,698

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 474559   Start Trial
Australia 2002305758   Start Trial
Australia 2006235929   Start Trial
Australia 2009200966   Start Trial
Australia 2009290712   Start Trial
Brazil PI0918492   Start Trial
Canada 2449098   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
Harvard Business School
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.